Outputs (2)

Non-inferiority trials in stroke research: what are they, and how should we interpret them? (2025)
Journal Article
Li, L., Lioutas, V.-A., Akyea, R. K., Gerner, S., Lau, K. K., Ramage, E., Katsanos, A. H., Howard, G., & Bath, P. M. (2025). Non-inferiority trials in stroke research: what are they, and how should we interpret them?. Journal of Stroke, 27(1), 41-51. https://doi.org/10.5853/jos.2024.03923

Randomized clinical trials are important in both clinical and academic stroke communities with increasing numbers of new design concepts emerging. One of the “less traditional” designs that have gained increasing interest in the last decade is non-in... Read More about Non-inferiority trials in stroke research: what are they, and how should we interpret them?.

Recombinant Human Tissue Kallikrein-1 for Treating Acute Ischemic Stroke and Preventing Recurrence (2025)
Journal Article
Kasner, S. E., Bath, P. M., Hill, M. D., Volpi, J. J., Giuffre, M., Masuoka, L., Wambeke, D., & Madeddu, P. R. (2025). Recombinant Human Tissue Kallikrein-1 for Treating Acute Ischemic Stroke and Preventing Recurrence. Stroke, https://doi.org/10.1161/STROKEAHA.124.048858

Novel strategies are needed for the treatment of acute ischemic stroke when revascularization therapies are not clinically appropriate or are unsuccessful. Recombinant human tissue kallikrein-1 (rKLK1), a bradykinin-producing enzyme, offers a promis... Read More about Recombinant Human Tissue Kallikrein-1 for Treating Acute Ischemic Stroke and Preventing Recurrence.